Policy & Regulation
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
19 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from the Phase 3 TALAPRO-3 study evaluating TALZENNA (talazoparib) in combination with...
Specific Biologics and Western University win grant to develop ML platform to accelerate development of Dualase-based therapeutics 
19 March 2026 - Canadian biotechnology company Specific Biologics Inc announced on Wednesday that together with Western University it has been awarded a grant of more than CAD1.8m from Genome Canada a...
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
19 March 2026 - Swedish life science tools company Mabtech announced on Wednesday a strategic collaboration with Sai Life Sciences, a global Contract Research Organisation (CRO).Under the agreement, S...
IsomAb names new CEO
19 March 2026 - UK biotechnology company IsomAb Ltd announced on Wednesday the appointment of Dr Philip Brainin as chief executive officer and member of the board of directors.IsomAb is developing iso...
Mirecule expands collaboration with Sanofi to advance FSHD therapy
18 March 2026 - Mirecule Inc, a developer of Antibody RNA Conjugate (ARC) therapeutics targeting rare neuromuscular diseases, on Wednesday announced an expansion of its strategic collaboration with Fr...
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designati...